Information for Patients and Physicians

Solid tumors encompass a range of cancer types that are named for the type of cells that form them, such as ovarian, breast, pancreas and lung.

Renal cell carcinoma forms in the kidney. It is the most common type of kidney cancer in adults, representing approximately 90 percent of cases. The American Cancer Society estimates that there will be approximately 61,000 new cases of kidney cancer in the United States during 2011, and that about 13,000 people will die from the disease.

Pancreatic cancer is a fast-growing and difficult to detect form of cancer that affects the pancreas. According to the American Cancer Society, the annual incidence of pancreatic cancer is estimated to be greater than 44,000 cases, and more than 37,000 people are expected to die from the disease in 2011.

Prostate cancer forms in tissues of the prostate, a gland in the male reproductive system. According to the American Cancer Society, more than 240,800 new cases of prostate cancer will be diagnosed in the United States during 2011, making it the most commonly diagnosed form of cancer. More than 37,000 men are expected to die of prostate cancer in the United States during 2011.

For more detailed information about the clinical trial summarized below, visit the trial listing at www.clinicaltrials.gov.

 

SOLID TUMORS AND OTHER CLINICAL TRIALS
Brentuximab vedotin phase II trial for CD30-positive non-lymphoma malignancies

Single-agent trial assessing the antitumor activity and safety as well as the relationship of CD30 expression with antitumor activity of brentuximab vedotin in patients with CD30-positive non-lymphoma malignancies, including multiple myeloma, leukemia and solid tumors, who have failed, refused or have been deemed ineligible for standard therapy
See study details ›

SGN-75 phase I trial for renal cell carcinoma

Single-agent dose-escalation trial assessing the safety, tolerability, pharmacokinetics and antitumor activity of SGN-75 in patients with metastatic renal cell carcinoma or relapsed or refractory non-Hodgkin lymphoma; enrollment to this trial is complete

See study details ›

ASG-5ME phase I trial for pancreatic cancer

Single-agent, open-label, dose-escalation trial to evaluate the safety and tolerability of ASG-5ME and to identify the maximum tolerated dose in patients with metastatic pancreatic cancer; enrollment to this trial is complete

See study details ›

ASG-5ME phase I trial for prostate cancer

Single-agent, open label, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of ASG-5ME, and to identify the maximum tolerated dose in patients with castration-resistant prostate cancer

See study details ›

ASG-22ME phase I trial for solid tumors

Single-agent, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetic profile and antitumor activity of
ASG-22ME

See study details ›

PATIENT RESOURCES

If you have questions about the solid tumor clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer and participating in clinical trials can be found on the following web sites.

Privacy Policy  |  Legal Notice